Denali Therapeutics Inc. (DNLI)
Develops medicines for brain diseases like Parkinson's and Alzheimer's using enzyme delivery technology.
$23.28-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+73.2%
The outlook
Denali Therapeutics is trading at $23.28 with strong analyst backing—16 analysts rate it a strong buy on average, and their consensus target sits roughly 47% above the current price. The stock is positioned above both its 50- and 200-day moving averages and sits in the upper portion of its 52-week range, reflecting sustained upward momentum.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 16 analysts
Price trendAbove its 50- & 200-day averages
52-week range73% of the way from its 52-week low to high
Price targetAvg target +47% vs current price
Analyst price target
~12-month · 16 analysts$34.31average target+47.4% vs now
Now $23.28
Low $25.00High $42.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.69B
52-wk high
$27.30
52-wk low
$12.58
50-day avg
$22.48
200-day avg
$19.67
Trailing P/E
—